KR940005280A - 과증식성 혈관 질환의 치료방법 - Google Patents

과증식성 혈관 질환의 치료방법 Download PDF

Info

Publication number
KR940005280A
KR940005280A KR1019930006958A KR930006958A KR940005280A KR 940005280 A KR940005280 A KR 940005280A KR 1019930006958 A KR1019930006958 A KR 1019930006958A KR 930006958 A KR930006958 A KR 930006958A KR 940005280 A KR940005280 A KR 940005280A
Authority
KR
South Korea
Prior art keywords
heparin
rapamycin
mammal
vascular disease
hyperproliferative
Prior art date
Application number
KR1019930006958A
Other languages
English (en)
Other versions
KR100284210B1 (ko
Inventor
뎀스터 미첼 로버트
스퀴쉬 스티븐
Original Assignee
이건 이. 버그
아메리칸 홈 프러덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/874,895 external-priority patent/US5288711A/en
Priority claimed from GB929217630A external-priority patent/GB9217630D0/en
Application filed by 이건 이. 버그, 아메리칸 홈 프러덕츠 코포레이션 filed Critical 이건 이. 버그
Publication of KR940005280A publication Critical patent/KR940005280A/ko
Application granted granted Critical
Publication of KR100284210B1 publication Critical patent/KR100284210B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 라파마이신과 해파린의 배합물의 증식 억제 유효랑을 투여함으로써 포유동물에서의 과증식성 혈관질환을 예방하거나 치료하는 방법을 제공한다.

Description

과증식성 혈관 질환의 치료방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (18)

  1. 과증식성 혈관 질환의 예방이나 치료를 필요로 하는 포유동물에게 증식억제 유효량의 라파마이신 및 헤파린을 동시에, 별도로 또는 연속적으로 투여함을 특징으로 하여 상기한 예방 또는 치료를 필요로 하는 포유동물에게 과증식성 혈관 질환을 예방하거나 치료하는 방법.
  2. 제1항에 있어서, 과증식성 혈관 질환이 동맥내막 평활근 세포 비후, 협착 및 혈관 페쇄로 이루어진 그룹으로 부터 선택되는 방법.
  3. 제2항에 있어서, 라파마이신과 헤파린의 배합물을 포유동물이 경피의, 관강을 통한 관상 혈관형성술을 받을 때 동시에 투여하는 방법.
  4. 제3항에 있어서, 과증식성 혈관 질환이 협착인 방법.
  5. 제2항에 있어서, 라파마이신과 헤파린의 배합물을 포유동물이 경피의, 관강을 통한 관상 혈관형성술을 받은 후에 투여하는 방법.
  6. 제5항에 있어서, 과증식성 혈관 질환이 협착인 방법.
  7. 제2항에 있어서. 포유동물이 생물학적으로 또는 기계적으로 매개된 혈관 손상을 입음과 동시에 라파마이신과 헤파린의 배합물을 투여하는 방법.
  8. 제2항에 있어서. 포유동물이 생물학적으로 또는 기계적으로 매개된 혈관 손상을 입음과 동시에 라파마이신과 헤파린의 배합물을 투여하는 방법.
  9. 제1항 내지 제8항중 어느 한 항에 있어서, 리파라이신 및 헤파린을 각각 경구, 비경구, 힐관내, 비내, 기관지내, 경피 또는 직장내로부터 선택된 경로에 의해 투여하거나. 둘 다를 함침된 혈관 스테드를 통해 투여하는 방법.
  10. 포유동물에게 과증식성 혈관 질환을 예방하거나 치료할 때 동시에, 별도로 또는 연속적으로 사용하기 위한 배합된 제제로서의 라파마이신 또는 헤파린을 함유하는 생성물.
  11. 포유동물에게 과증식성 혈관 질환을 치료하거나 예방할 때 동시에, 별도로 또는 연속적으로 사용하기 위한 배합된 약제의 제조에 있어서 라파마이신과 헤파린의 용도.
  12. 제9항 또는 제10항에 있어서, 과증식성 혈관 질환이 동맥내막 평활근 세포 비후, 협착 및 혈관 페쇄로부터 선택되는 생성물 또는 용도.
  13. 라파마이신 및 헤파린 및 겅우에 따라 약물학적으로 허용되는 담체를 포함하는 약제학적 조성물.
  14. 라파마이신과 헤파린의 배합물의 증식억제량 및 약물학적으로 허용되는 담체를 포함하는, 포유동물에서 과증식성 혈관 질환을 치료하거나 예방하기 위한 약제학적 조성물.
  15. 제10항 내지 제14항중 어느 한 항에 있어서, 라파마이신 및 헤파린이 분리되거나 혼합된 단위 투여 형태인 생성물, 용도 또는 조성물.
  16. 제15항에 있어서, 라파마이신의 치료할 포유동물의 체중을 기준으로 하여 0.005 내지 20㎎/㎏의 1일 투여량을 제공하기에 충분한 양인 생성물, 용도 또는 조성물.
  17. 제15항 또는 제16항에 있어서, 헤파린이 치료할 포유동물의 체중을 기준으로 하여 1 내지 100㎎/㎏의 1일 투여량을 제공하기에 충분한 양인 생성물, 용도 또는 조성물.
  18. 제1항 내지 제17항중 어느 한 항에 있어서, 헤파린이 비-항응고제 형태인 방법, 생성물, 용도 또는 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930006958A 1992-04-28 1993-04-26 과증식성 혈관 질환 치료용 배합 제제 KR100284210B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US07/874,895 US5288711A (en) 1992-04-28 1992-04-28 Method of treating hyperproliferative vascular disease
US7/874,895 1992-04-28
US9217630.4 1992-08-19
GB929217630A GB9217630D0 (en) 1992-08-19 1992-08-19 Method of treating hyperproliferative vascular disease
GB9217630.4 1992-08-19

Publications (2)

Publication Number Publication Date
KR940005280A true KR940005280A (ko) 1994-03-21
KR100284210B1 KR100284210B1 (ko) 2001-03-02

Family

ID=26301459

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930006958A KR100284210B1 (ko) 1992-04-28 1993-04-26 과증식성 혈관 질환 치료용 배합 제제

Country Status (15)

Country Link
EP (1) EP0568310B1 (ko)
JP (1) JP2550277B2 (ko)
KR (1) KR100284210B1 (ko)
AT (1) ATE135226T1 (ko)
AU (1) AU670937B2 (ko)
BR (1) BR9301667A (ko)
CA (1) CA2094858C (ko)
DE (1) DE69301754T2 (ko)
DK (1) DK0568310T3 (ko)
ES (1) ES2085720T3 (ko)
GR (1) GR3019380T3 (ko)
HK (1) HK109097A (ko)
HU (1) HU215388B (ko)
SG (1) SG43030A1 (ko)
TW (1) TW224051B (ko)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435318D1 (de) 1993-01-28 2010-12-09 Boston Scient Ltd Therapeutische inhibitoren der zellen der glatten gefässmuskulatur
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
NZ511762A (en) 1993-07-19 2003-09-26 Univ British Columbia Anti-angiogenic compositions and methods of use
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5618837A (en) * 1995-06-07 1997-04-08 Zymogenetics, Inc. PDGF antagonists III
CZ292233B6 (cs) 1995-06-09 2003-08-13 Novartis Ag Deriváty rapamycinu a jejich použití jako léčiv
WO1997002036A1 (en) * 1995-06-30 1997-01-23 Zymogenetics, Inc. 4-(2-(n-2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas as pdgf antagonists
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
IT1289815B1 (it) 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7445792B2 (en) 2003-03-10 2008-11-04 Abbott Laboratories Medical device having a hydration inhibitor
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US8029561B1 (en) 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) * 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
WO2001001957A1 (en) * 1999-05-27 2001-01-11 Biocompatibles Limited Local drug delivery
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
DE60114406T2 (de) * 2000-05-12 2006-08-03 Cordis Corp., Miami Lakes Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
AU2005202474B2 (en) * 2000-05-12 2007-09-06 Cardinal Health 529, Llc Delivery devices for treatment of vascular disease
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US6746773B2 (en) 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
WO2002026139A1 (en) * 2000-09-29 2002-04-04 Cordis Corporation Coated medical devices
AU1129902A (en) * 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
ATE387169T1 (de) 2000-10-16 2008-03-15 Conor Medsystems Inc Expandierbare medizinische vorrichtung zum zuführen eines heilmittels
US8182527B2 (en) 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
JP2005533604A (ja) * 2002-07-25 2005-11-10 アバンテック バスキュラー コーポレーション 治療薬を送達する装置とこれに関する方法
US7438925B2 (en) * 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
US8791171B2 (en) 2003-05-01 2014-07-29 Abbott Cardiovascular Systems Inc. Biodegradable coatings for implantable medical devices
EP2329852A1 (en) 2004-03-26 2011-06-08 SurModics, Inc. Composition and method for preparing biocompatible surfaces
EP1735024A1 (en) 2004-03-26 2006-12-27 SurModics, Inc. Process and systems for biocompatible surfaces
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
CA2656635C (en) 2006-07-03 2013-05-28 Hemoteq Ag Stent with polymeric coating comprising rapamycin as an active agent
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
RU2447901C2 (ru) 2007-01-21 2012-04-20 Хемотек Аг Медицинский продукт для лечения обтураций просветов организма и для предупреждения угрожающих повторных обтураций
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US20090074831A1 (en) * 2007-09-18 2009-03-19 Robert Falotico LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
WO2009089549A1 (en) 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
EP3064230B1 (en) 2009-07-10 2019-04-10 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
WO2011008393A2 (en) 2009-07-17 2011-01-20 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating

Also Published As

Publication number Publication date
EP0568310A1 (en) 1993-11-03
DE69301754T2 (de) 1996-08-08
BR9301667A (pt) 1993-11-03
JP2550277B2 (ja) 1996-11-06
HK109097A (en) 1997-08-22
ATE135226T1 (de) 1996-03-15
CA2094858A1 (en) 1993-10-29
GR3019380T3 (en) 1996-06-30
SG43030A1 (en) 1997-10-17
AU3713693A (en) 1993-11-04
HU215388B (hu) 1998-12-28
HU9301216D0 (en) 1993-07-28
AU670937B2 (en) 1996-08-08
DK0568310T3 (da) 1996-07-29
JPH0680573A (ja) 1994-03-22
KR100284210B1 (ko) 2001-03-02
TW224051B (ko) 1994-05-21
HUT64231A (en) 1993-12-28
EP0568310B1 (en) 1996-03-13
ES2085720T3 (es) 1996-06-01
DE69301754D1 (de) 1996-04-18
CA2094858C (en) 2004-06-15

Similar Documents

Publication Publication Date Title
KR940005280A (ko) 과증식성 혈관 질환의 치료방법
KR930016102A (ko) 과증식 혈관 질환 치료용 조성물
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
HK1006222A1 (en) Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast
NO20013727L (no) Anvendelse av Botulinumtoksin B for fremstilling av et medikament
EP1649853A3 (en) Microtubule stabilizing agents for treating atherosclerosis or restenosis
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
IL107109A0 (en) Compounds for modifying drug resistance and pharmaceutical compositions containing the same
CY1109827T1 (el) Χρηση της αλλαντοτοξινης για την αγωγη δυσκολα αντιμετωπισιμης δυσλειτουργιας κενωσης
ES2123642T3 (es) Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m.
IL86633A (en) 2-furanone derivatives, their preparation and pharmaceutical compositions containing them
DE69029693D1 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
ATE79256T1 (de) Zusammensetzung gegen coccidiosis.
AR016044A1 (es) Composiciones farmaceuticas que comprenden cantidades antialergenicas efectivas de descarboniletoxiloratadina
KR920702225A (ko) 약학 조성물
GR3020575T3 (en) New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
DE69124380D1 (de) Verfahren und zusammensetzungen für die behandlung durch t-zellen vermittelter krankheiten
FR2701952B1 (fr) Nouveaux dérivés cyclopeptidiques de l'angiopeptine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
ATE106874T1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES2034062T3 (es) Eteres y tioeteres que tienen actividad terapeutica, su preparacion y composiciones farmaceuticas que los contienen.
KR930019221A (ko) 성인병 예방 및 치료용 순환계용계약 조성물
FR2709126B1 (fr) Nouveaux dérivés de naphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
KR950703966A (ko) 협착증 억제를 위한 미코페놀산, 미코페놀레이트 모페틸 또는 이의 유도체의 용도(Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121129

Year of fee payment: 13

EXPY Expiration of term